Oragenics completes key FDA-recognized study for ONP-002

Oragenics has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury. The recent study shows that the drug successfully targets areas inside the nose that are connected to the brain. This makes it more likely to reach and treat the brain after a concussion. Intranasal casting studies are valued by the FDA for pharmaceuticals delivered via the nasal passage and accept such studies in FDA submissions. Oragenics is now preparing to move forward with human testing in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.